Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.
Together with a team at the Erasmus Medical Center in Rotterdam, LMU researchers have developed a candidate vaccine directed against the avian flu virus H5N1 and have now carried out the first tests in humans.
Merck & Co., a top creator and seller of vaccines, has joined the fight against Ebola, the often-fatal hemorrhagic virus that's been ravaging parts of West Africa for months.
The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information ...
New results from a safety and immunogenicity study, which included a challenge phase to test efficacy, indicate that a live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate, given in combination with a ...
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.
Experimental vaccines to treat Ebola could be ready for use in African countries badly hit by the deadly virus early next year, the World Health Organization said Friday.
The long-observed association between pneumonia and heart failure now has more physical evidence, thanks to research in the School of Medicine at The University of Texas Health Science Center at San Antonio.
New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster shot made a different way.
In the past year, the largest and deadliest outbreak of the Ebola virus has spread through West Africa—now with confirmed cases in five countries—and more than half of those who have contracted the virus ...
Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Safety trials on an Ebola vaccine are being fast-tracked, meaning it could be given to healthy volunteers as early as September, researchers said Thursday.
An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted ...
Scientists are racing to begin the first human safety tests of two experimental Ebola vaccines, but it won't be easy to prove that the shots and other potential treatments in the pipeline really work.
There is no vaccine on the world market to protect against the deadly Ebola virus, but experts say the fast-growing outbreak in West Africa is speeding efforts to test one.